Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. (TARS) — VMCI valuation read

TARS screens at VMCI 44/100, a 6-point gap below the Healthcare sector median (50). For a mid-cap Tarsus Pharmaceuticals, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

TARS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: TARS trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 3.3x is the binding constraint on the bear case, which sets the rate-cycle exposure for Tarsus Pharmaceuticals, Inc..

TARS rose 2.8% over the trailing 7 days, with a +5.7% read on a 30-day basis.